Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha announced that longer-term data from the REVEAL Part A trial of TSHA-102 demonstrated broad functional improvements that deepened over at least 12 months, regardless of age or disease severity. The presentations highlighted natural history data confirming a developmental plateau after age 6 and validated the Rett Syndrome Developmental Milestone Assessment as a psychometrically sound, FDA-supported primary endpoint.
Key figures
- Follow up duration
- ≥12 months
- Developmental plateau age
- 6 years
- Patient population us eu uk
- 15,000 to 20,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.